Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2014 2
2016 1
2017 4
2018 6
2019 17
2020 16
2021 18
2022 25
2023 26
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Results by year

Filters applied: . Clear all
Page 1
Lanadelumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30272897 Free Books & Documents. Review.
No information is available on the clinical use of lanadelumab during breastfeeding. Because lanadelumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destro …
No information is available on the clinical use of lanadelumab during breastfeeding. Because lanadelumab is a large protein mo …
Lanadelumab: A Review in Hereditary Angioedema.
Syed YY. Syed YY. Drugs. 2019 Nov;79(16):1777-1784. doi: 10.1007/s40265-019-01206-w. Drugs. 2019. PMID: 31560114 Review.
Lanadelumab therapy was associated with clinically meaningful improvements in HAE-specific quality of life. Lanadelumab was generally well tolerated. The most common adverse events with lanadelumab were injection-site reactions, which were generally mild and …
Lanadelumab therapy was associated with clinically meaningful improvements in HAE-specific quality of life. Lanadelumab was ge …
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M; HELP Investigators. Banerji A, et al. JAMA. 2018 Nov 27;320(20):2108-2121. doi: 10.1001/jama.2018.16773. JAMA. 2018. PMID: 30480729 Free PMC article. Clinical Trial.
Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 lanadelumab to placebo; patients assigned to lanadelumab were further randomized 1:1:1 to 1 of the 3 dose regimens. ...The most com …
Patients were randomized between March 3, 2016, and September 9, 2016; last day of follow-up was April 13, 2017. Randomization was 2:1 la …
Lanadelumab.
[No authors listed] [No authors listed] 2019 Apr 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2019 Apr 12. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643419 Free Books & Documents. Review.
Lanadelumab is a human IgG1 monoclonal antibody to kallikrein which blocks the activation of bradykinin, a potent vasodilator responsible for the attacks of swelling, inflammation and pain in hereditary angioedema (HAE). Lanadelumab has been linked to a low rate of …
Lanadelumab is a human IgG1 monoclonal antibody to kallikrein which blocks the activation of bradykinin, a potent vasodilator respons …
Lanadelumab to treat hereditary angioedema.
Wedi B. Wedi B. Drugs Today (Barc). 2019 Jul;55(7):439-448. doi: 10.1358/dot.2019.55.7.2985293. Drugs Today (Barc). 2019. PMID: 31347612 Review.
Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacks of hereditary angioedema (HAE). ...Lanadelumab has the potential to change the approach from on-demand treatment to prophylaxis in HAE. ...
Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacks of hereditary angioedema (HA …
Lanadelumab for hereditary angioedema.
[No authors listed] [No authors listed] Aust Prescr. 2022 Apr;45(2):65. doi: 10.18773/austprescr.2022.017. Epub 2022 Mar 4. Aust Prescr. 2022. PMID: 35592365 Free PMC article. Review. No abstract available.
Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A, Bernstein JA, Johnston DT, Lumry WR, Magerl M, Maurer M, Martinez-Saguer I, Zanichelli A, Hao J, Inhaber N, Yu M, Riedl MA; HELP OLE Investigators. Banerji A, et al. Allergy. 2022 Mar;77(3):979-990. doi: 10.1111/all.15011. Epub 2021 Aug 13. Allergy. 2022. PMID: 34287942 Free PMC article. Clinical Trial.
BACKGROUND: The aim was to evaluate long-term effectiveness and safety of lanadelumab in patients 12 y old with hereditary angioedema (HAE) 1/2 (NCT02741596). METHODS: Rollover patients completing the HELP Study and continuing into HELP OLE received one lanadelumab …
BACKGROUND: The aim was to evaluate long-term effectiveness and safety of lanadelumab in patients 12 y old with hereditary angioedema …
Lanadelumab for the treatment of hereditary angioedema.
Wu MA. Wu MA. Expert Opin Biol Ther. 2019 Dec;19(12):1233-1245. doi: 10.1080/14712598.2019.1685490. Epub 2019 Nov 4. Expert Opin Biol Ther. 2019. PMID: 31657963 Review.
With the aim of improving patients' quality of life, the therapeutic scenario has expanded over the years.Areas covered: The focus of the present review is lanadelumab, a fully human, kappa-light-chain, monoclonal immunoglobulin G1 against plasma kallikrein, currently appr …
With the aim of improving patients' quality of life, the therapeutic scenario has expanded over the years.Areas covered: The focus of the pr …
Lanadelumab: First Global Approval.
Syed YY. Syed YY. Drugs. 2018 Oct;78(15):1633-1637. doi: 10.1007/s40265-018-0987-2. Drugs. 2018. PMID: 30267321 Review.
Shire is developing lanadelumab (Takhzyro) for the prevention of hereditary angioedema (HAE) attacks. Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein. ...
Shire is developing lanadelumab (Takhzyro) for the prevention of hereditary angioedema (HAE) attacks. Lanadelumab is a fully h …
Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A, Senter R, Wu MA, Zanichelli A, Cicardi M. Valerieva A, et al. Expert Rev Clin Immunol. 2019 Dec;15(12):1239-1248. doi: 10.1080/1744666X.2020.1693261. Epub 2019 Nov 19. Expert Rev Clin Immunol. 2019. PMID: 31721602 Review.
Attacks recur with unpredictable frequency and severity, laryngeal edema is potentially lethal, and the disease burden may severely disrupt patients' lives.Areas covered: This review provides an overview of lanadelumab, a human monoclonal antibody targeted against plasma k …
Attacks recur with unpredictable frequency and severity, laryngeal edema is potentially lethal, and the disease burden may severely disrupt …
111 results